<?xml version="1.0" encoding="UTF-8"?>
<p>At least 16 different trials for SARS-CoV-2 are already registered in the Chinese clinical trial registry (
 <uri xlink:href="http://www.chictr.org.cn" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.chictr.org.cn</uri>) testing the efficacy of chloroquine and hydroxychloroquine. In addition, hydroxychloroquine is now under evaluation in the U.S. (NCT04308668) as a post-exposure prophylaxis/preemptive therapy for SARS-CoV-2 infection. Recently the NIH guidelines panel for COVID-19 treatment recommended against the use of chloroquine or hydroxychloroquine for the treatment of COVID-19, except in a clinical trial. The panel also recommends against the use of high-dose chloroquine (600 mg twice daily for 10 days) for the treatment of COVID-19 [
 <xref rid="B165-ijms-21-05559" ref-type="bibr">165</xref>].
</p>
